Jakarta, CNBC Indonesia – Moderna Inc claims vaccine His Covid-19 was 93% effective four to six months after the second dose of injection. This shows the efficacy of the Moderna vaccine has not changed much from the initial efficacy which reached 94% against Covid-19.
This claim compares favorably with data released by its competitor, Pfizer-BioNTech which showed a decrease in vaccine efficacy by 6% every two months and to 84% six months after the second dose was injected.
“We are very pleased that the efficacy of our Covid-19 vaccine has stabilized at 93% in four to six months,” said Moderna Chief Executive Stephane Bancel. “This strong duration will benefit the hundreds of millions of people who have been injected with the Moderna vaccine.”
Moderna reveals in this ongoing study, the three different booster candidates used induce a strong antibody response to the variant of concern. These include Gamma, Beta, and Delta variants.
The long-lasting effectiveness of the vaccine means the recipient may take longer to receive booster injections or additional doses to increase antibodies to defend the body against Covid-19 infection.
The presence of the delta variant of Covid-19 has sparked debate among experts whether it is necessary to give a booster or an additional dose of vaccine so that the body is better at fighting the delta variant. Understandably, this variant, which was first discovered in India, is very contagious and can make sufferers need to be hospitalized.
Information only, vaccines present two immune systems against viruses. Namely, antibodies that normally decline over time and T-cells that provide protection from severe disease, as well as provide resistance.
T-cells are a type of white blood cell that play different roles in defending the body against invading viruses. Antibodies prevent viruses from attacking cells but do not survive as long as T-cells.
(roy/miq)
– .
